Genmab AS (GEN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Genmab AS (GEN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9942
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:デンマーク
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Genmab A/S (Genmab) is a biotechnology company that develops differentiated human antibody therapeutics for the treatment of cancer. The company’s marketed antibody, ofatumumab (Arzerra) and Daratumumab (Darzalex) are indicated for the treatment of chronic lymphocytic leukemia and multiple myeloma respectively. Genmab’s products are based on three next generation antibody technologies, namely, HexaBody, DuoBody, and antibody drug conjugate (ADC) technologies. The company works in partnership with various pharmaceutical and biotechnology companies for the co-development and commercialization of antibody-based products. It operates in Denmark, the Netherlands, and the US. Genmab is headquartered in Copenhagen, Denmark.

Genmab AS (GEN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Genmab A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Genmab A/S, Medical Devices Deals, 2012 to YTD 2018 10
Genmab A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Genmab A/S, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Genmab Acquires Antibody Assets from iDD Biotech 13
Partnerships 14
Mabimmune and Genmab Enter into Research Collaboration 14
Genmab Enters into Co-Development Agreement with BioNTech 15
BioNovion Enters into Agreement with Genmab to Discover and Develop Multiple Bispecific Antibody Products 16
Genmab Enters into Research Agreement with Seattle Genetics 17
Ventana Medical Systems Enters Into Co-Development Agreement With Genmab 18
MAB Discovery Enters into Research Agreement with Genmab for Therapeutic Antibody Products 19
Genmab Enters Into Co-Development Agreement With ADC Therapeutics 20
Genmab Enters into Co-Development Agreement with ADC Therapeutics 21
Genmab Enters Into Agreement With Kyowa Hakko Kirin For Bispecific Antibodies 22
Licensing Agreements 23
Genmab Enters into Licensing Agreement with Immatics Biotechnologies 23
Genmab Enters into Licensing Agreement with Gilead Sciences 24
Novo Nordisk Expands Licensing Agreement with Genmab 25
Genmab Enters into Licensing Agreement with Bristol-Myers Squibb 26
Genmab Enters into Licensing Agreement with Janssen Biotech for Daratumumab 27
Genmab Expands Licensing Agreement With Janssen Biotech 29
Genmab Enters into Licensing Agreement with Janssen Biotech for DuoBody Technology 30
Genmab Enters Into Licensing Agreement With Cormorant Pharma For HuMax-IL8 31
Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 32
Equity Offering 33
Genmab Raises USD1.2 Million in Private Placement of Shares up on Exercise of Warrants 33
Genmab to Raise USD4.8 Million in Private Placement of Shares upon Exercise of Warrants 34
Genmab Completes Private Placement of Shares for USD181.3 Million 35
Genmab Completes Private Placement Of Shares For US$2 Million Upon Exercise Of Warrants 36
Genmab Completes Private Placement Of Shares For US$5 Million Upon Exercise Of Warrants 37
Asset Transactions 38
Genmab Sells Brooklyn Park Manufacturing Facility To Baxter Healthcare For US$10 Million 38
Acquisition 39
Meditor European Master Fund Sells Its Stake In Genmab 39
Genmab A/S – Key Competitors 40
Genmab A/S – Key Employees 41
Genmab A/S – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Recent Developments 43
Financial Announcements 43
May 08, 2018: Genmab: Interim Report First Quarter 2018 43
Feb 21, 2018: Genmab 2017 Annual Report 44
Nov 08, 2017: Genmab Announces Financial Results for the First Nine Months of 2017 46
Aug 09, 2017: Genmab Announces Financial Results for the First Half of 2017 47
May 10, 2017: Genmab Announces Financial Results for the First Quarter of 2017 48
Feb 22, 2017: Genmab 2016 Annual Report 53
Jan 24, 2017: Genmab reports net sales for DARZALEX in 2016 54
Corporate Communications 55
Feb 08, 2017: Genmab Appoints Judith Klimovsky, MD, as Chief Development Officer 55
Product News 56
06/29/2018: HuMax-AXL-ADC Progress Triggers Milestone Payment to Seattle Genetics 56
05/17/2018: Genmab Announces to Present Abstract on CD3xCD20 at 23rd EHA Annual Congress 57
04/20/2017: Genmab To Present Poster Presentations On HuMax-AXL-ADC at 2017 ASCO Annual Meeting 58
Other Significant Developments 59
Dec 11, 2017: Genmab’s 2017 R&D Update 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60

List of Tables
Genmab A/S, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Genmab A/S, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Genmab A/S, Deals By Therapy Area, 2012 to YTD 2018 9
Genmab A/S, Medical Devices Deals, 2012 to YTD 2018 10
Genmab A/S, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Genmab Acquires Antibody Assets from iDD Biotech 13
Mabimmune and Genmab Enter into Research Collaboration 14
Genmab Enters into Co-Development Agreement with BioNTech 15
BioNovion Enters into Agreement with Genmab to Discover and Develop Multiple Bispecific Antibody Products 16
Genmab Enters into Research Agreement with Seattle Genetics 17
Ventana Medical Systems Enters Into Co-Development Agreement With Genmab 18
MAB Discovery Enters into Research Agreement with Genmab for Therapeutic Antibody Products 19
Genmab Enters Into Co-Development Agreement With ADC Therapeutics 20
Genmab Enters into Co-Development Agreement with ADC Therapeutics 21
Genmab Enters Into Agreement With Kyowa Hakko Kirin For Bispecific Antibodies 22
Genmab Enters into Licensing Agreement with Immatics Biotechnologies 23
Genmab Enters into Licensing Agreement with Gilead Sciences 24
Novo Nordisk Expands Licensing Agreement with Genmab 25
Genmab Enters into Licensing Agreement with Bristol-Myers Squibb 26
Genmab Enters into Licensing Agreement with Janssen Biotech for Daratumumab 27
Genmab Expands Licensing Agreement With Janssen Biotech 29
Genmab Enters into Licensing Agreement with Janssen Biotech for DuoBody Technology 30
Genmab Enters Into Licensing Agreement With Cormorant Pharma For HuMax-IL8 31
Open Monoclonal Technology Enters into Licensing Agreement with Genmab for OmniRat, OmniMouse and OmniFlic 32
Genmab Raises USD1.2 Million in Private Placement of Shares up on Exercise of Warrants 33
Genmab to Raise USD4.8 Million in Private Placement of Shares upon Exercise of Warrants 34
Genmab Completes Private Placement of Shares for USD181.3 Million 35
Genmab Completes Private Placement Of Shares For US$2 Million Upon Exercise Of Warrants 36
Genmab Completes Private Placement Of Shares For US$5 Million Upon Exercise Of Warrants 37
Genmab Sells Brooklyn Park Manufacturing Facility To Baxter Healthcare For US$10 Million 38
Meditor European Master Fund Sells Its Stake In Genmab 39
Genmab A/S, Key Competitors 40
Genmab A/S, Key Employees 41
Genmab A/S, Subsidiaries 42

List of Figures
Genmab A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Genmab A/S, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Genmab A/S, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Genmab A/S, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Genmab AS (GEN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bandera Electric Cooperative, Inc.:企業の戦略的SWOT分析
    Bandera Electric Cooperative, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major …
  • Trina Solar Ltd:企業の戦略的SWOT分析
    Trina Solar Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Okamoto Industries, Inc.
    Okamoto Industries, Inc. - Strategy, SWOT and Corporate Finance Report Summary Okamoto Industries, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Hoteli-Metropol AD Ohrid:企業の戦略・SWOT・財務情報
    Hoteli-Metropol AD Ohrid - Strategy, SWOT and Corporate Finance Report Summary Hoteli-Metropol AD Ohrid - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Bespak Europe Ltd:企業の製品パイプライン分析2018
    Summary Bespak Europe Ltd (Bespak), a subsidiary of Consort Medical plc is a medical device company that provides inhalation systems. The company provides products such as inhalation devices, injectables, medical check valves and nasal products. Its inhalation devices comprise dose counting actuator …
  • Presidio Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Presidio Pharmaceuticals Inc (Presidio) is a clinical-stage pharmaceutical company that discovers and develops small-molecule antiviral therapeutics. The company’s products include HCV NS5A, NS5B proteins, lead pan-genotypic HCV NS5A inhibitor, ravidasvir hydrochloride, protease inhibitor, f …
  • IBEX Technologies Inc (IBT):企業の財務・戦略的SWOT分析
    Summary IBEX Technologies Inc (IBEX) is a manufacturer and marketer of high-purity proprietary enzymes and recombinant from flavobacterium heparinum. The company provides enzymes such as heparinase I, heparinase II, heparinase III, chondroitinase AC and chondroitinase B. Its assays allow for the stu …
  • NetSuite Inc.:企業の戦略的SWOT分析
    NetSuite Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Stantec Inc (STN)-石油・ガス分野:企業M&A・提携分析
    Summary Stantec Inc. (Stantec) is a consulting services company offering architectural, engineering, and environmental services. Its service portfolio includes architecture and interior design, building engineering, community design services, geomatics, geotechnical engineering, landscape architectu …
  • Bank of Montreal:企業の戦略・SWOT・財務分析
    Bank of Montreal - Strategy, SWOT and Corporate Finance Report Summary Bank of Montreal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Stanley Black & Decker Inc:戦略・SWOT・企業財務分析
    Stanley Black & Decker Inc - Strategy, SWOT and Corporate Finance Report Summary Stanley Black & Decker Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Philippine Bank Of Communications
    Philippine Bank Of Communications - Strategy, SWOT and Corporate Finance Report Summary Philippine Bank Of Communications - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • China Bohai Bank Co., Ltd:企業の戦略・SWOT・財務情報
    China Bohai Bank Co., Ltd - Strategy, SWOT and Corporate Finance Report Summary China Bohai Bank Co., Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Kadimastem Ltd (KDST):企業の財務・戦略的SWOT分析
    Summary Kadimastem Ltd (Kadimastem) is a clinical stage biopharmaceutical company that develops industrial regenerative medicines to treat neuro-degenerative diseases. Its technology platform enables the manufacturing of islet-like endocrine cells (differentiated cells) and glia restricted progenito …
  • Diffusion Pharmaceuticals Inc (DFFN):製薬・医療:M&Aディール及び事業提携情報
    Summary Diffusion Pharmaceuticals Inc (Diffusion), formerly Diffusion Pharmaceuticals LLC is a clinical stage biotechnology company that develops standard of care therapies. The company improves cancer treatments such as radiation therapy and chemotherapy in treatment-resistant solid tumors, includi …
  • Schindler Holding Ltd.:企業の戦略・SWOT・財務分析
    Schindler Holding Ltd. - Strategy, SWOT and Corporate Finance Report Summary Schindler Holding Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Parexel International Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Parexel International Corp (Parexel) is a biopharmaceutical outsourcing service company which focuses on providing various services for managing the biopharmaceutical product lifecycle and for the development and commercialization of new medical therapies. It offers a comprehensive range of …
  • Chang Chun Petrochemical Co Ltd:企業の戦略的SWOT分析
    Chang Chun Petrochemical Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pro …
  • PBF Energy Inc. (PBF)-石油・ガス分野:企業M&A・提携分析
    Summary PBF Energy Inc. (PBF Energy) is an independent oil refining company. It owns and operates crude oil refineries and related facilities in the US. Its refining assets include Delaware City refinery, Delaware; Paulsboro refinery, New Jersey; Chalmette refinery, Louisiana, Torrance, California a …
  • Alcoa Corp:企業のM&A・事業提携・投資動向
    Alcoa Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Alcoa Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆